Literature DB >> 10894967

Muir-Torre syndrome - treatment with isotretinoin and interferon alpha-2a can prevent tumour development.

T Graefe1, U Wollina, H Schulz, W Burgdorf.   

Abstract

Muir-Torre syndrome is a genodermatosis in which multiple internal malignancies are associated with cutaneous sebaceous tumours and kerato-acanthomas. A 57-year-old man presented with multiple sebaceous tumours, kerato-acanthomas, verrucous carcinoma of the nose, renal cell and transitional cell carcinomas of the left kidney, adenoma of the colon and a positive family history of colon carcinoma. He was treated with interferon (IFN-alpha2a) s.c. 3 x 10(6) U three times a week along with 50 mg isotretinoin daily as well as topical isotretinoin gel. During a follow-up of 29 months, only 1 sebaceous skin tumour developed and was removed, whereas more than 30 such skin tumours had been surgically removed during the last 3 years. No evidence of internal tumour development or recurrence was found. The combination of IFN with retinoids seems to be of promise to prevent tumour development in Muir-Torre syndrome. Copyright 2000 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10894967     DOI: 10.1159/000018399

Source DB:  PubMed          Journal:  Dermatology        ISSN: 1018-8665            Impact factor:   5.366


  12 in total

1.  Use of oral isotretinoin in the management of rosacea.

Authors:  Hyunhee Park; James Q Del Rosso
Journal:  J Clin Aesthet Dermatol       Date:  2011-09

2.  Muir-Torre syndrome.

Authors:  Danielle Mintsoulis; Jennifer Beecker
Journal:  CMAJ       Date:  2015-11-02       Impact factor: 8.262

Review 3.  Updated Physician's Guide to the Off-label Uses of Oral Isotretinoin.

Authors:  Steven Brandon Nickle; Nathan Peterson; Michael Peterson
Journal:  J Clin Aesthet Dermatol       Date:  2014-04

4.  [Recurrent eyelid tumors with different dignities].

Authors:  U Löw; C S L Müller; E Zemova; F A Flockerzi; B Seitz
Journal:  Ophthalmologe       Date:  2019-11       Impact factor: 1.059

5.  [Muir-Torre syndrome with previously undescribed frameshift mutation in the MSH2 gene].

Authors:  B Gilly; A Unholzer; G Strobl-Wildemann; C Haas; H Starz; J Welzel
Journal:  Hautarzt       Date:  2013-04       Impact factor: 0.751

6.  [Sebaceous gland tumor with a rare gene mutation within a tumor syndrome: Muir-Torre syndrome].

Authors:  E Voigt; F Sommer; K D Geiger; L E Pillunat
Journal:  Ophthalmologe       Date:  2014-04       Impact factor: 1.059

Review 7.  The skin: a mirror to the gut.

Authors:  Vishal Ghevariya; Shashideep Singhal; Sury Anand
Journal:  Int J Colorectal Dis       Date:  2013-01-18       Impact factor: 2.796

8.  Sebaceous gland tumors and internal malignancy in the context of Muir-Torre syndrome. A case report and review of the literature.

Authors:  K Tsalis; K Blouhos; K Vasiliadis; T Tsachalis; S Angelopoulos; D Betsis
Journal:  World J Surg Oncol       Date:  2006-02-08       Impact factor: 2.754

9.  Muir-Torre syndrome in a haemodialysis patient.

Authors:  Evonne D Godfrey; Robert A Coward; Deepa Gharpuray-Pandit; Fiona Lalloo; Stuart McKirdy; Alexander Woywodt
Journal:  Clin Kidney J       Date:  2013-08

10.  Management of recurrent sebaceous gland carcinoma.

Authors:  Lindsay A McGrath; Zanna I Currie; Hardeep Singh Mudhar; Jennifer H Y Tan; Sachin M Salvi
Journal:  Eye (Lond)       Date:  2020-01-02       Impact factor: 3.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.